Treatment adjustment in biologic therapies for moderate‐to‐severe plaque psoriasis: a German retrospective chart review (TABU)

Abstract

SummaryBackground and objectivesFlexible biologic therapy dosing regimens in psoriasis management are common, but data from routine care in Germany are scarce. This study evaluated treatment adjustments for biologic therapies commonly prescribed in Germany.Patients and methodsCharts for up to 100 consecutive patients treated at 29 centers were reviewed. Data were extracted for adults (aged 18–65 years) with moderate‐to‐severe plaque psoriasis treated with adalimumab, guselkumab, ixekizumab, secukinumab, or ustekinumab for ≥ 36 weeks. The primary endpoint was time to first treatment adjustment. Secondary endpoints included frequency of and reasons for treatment adjustments. Time to treatment adjustment was analyzed using Kaplan‐Meier methods.ResultsAmong 982 patients, 297 treatment adjustments in 240 (24.4%) patients were identified. The mean (median; interquartile range) time to first treatment adjustment (n = 223) was 8.4 (4.0; 2.0–12.0) months (secukinumab: 14.1 [10.0; 4.0–21.0], adalimumab: 11.0 [7.0; 3.0–14.5], ustekinumab: 11.0 [6.0; 2.0–16.0], ixekizumab: 5.8 [3.0; 2.0–8.5], guselkumab: 5.1 [3.0; 2.0–7.0]). The most frequent adjustment type was starting concomitant treatment(s) (10.4% of patients); insufficient skin effectiveness was the most frequent reason for adjustment.ConclusionsBiological treatment adjustments are frequent in moderate‐to‐severe psoriasis; flexible dosing regimens would support optimal management.